Rec finished accum & now holding CTIX. I come here daily, listen more than I talk, and am grateful beyond measure for everyone's contributions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's the question of the hour- Bp3 timeline AND a qualified cost analysis vs speculation. Hope someone puts it to mgmt tomorrow.
I don't sense Mako/Rosen imparting any SP influence at this point. The recent dismissal checked my math on that one.
I see several variables keeping us sideways: (1)weakening cash position, in which SP would just continue trending downward were it not for: (a)modest optimism re one product scoring a partner/buyer, and (b)Optimism/speculation fueled by the timing of the C level hires. The latter has piqued my curiosity most.
Ha! I think Seiffert faithfully pre-wrote this story. Semper paratus!
For the sake of health and human safety, why can't FDA be privatized? Something like Underwriters Laboratories would be a quantum leap beyond that backward, recalcitrant government dinosaur..
Leo's a shareholder too. Has a lot more to lose than any of us retail. Aside from B, that's the main reason I'm in this.
"Soft-lock, Hard-lock".. What comes next? "Quasi-double-reverse data lock"? Lord almighty, can you imagine if these game-masters ever got control of the life-saving advancements in medicine? People the world over'd die waiting 20 years for- oh, wait..
Yes, visions of Rosen, the black knight from Monty Python, armless and legless and still spittin' fight as Sullivan exits the scene
Could happen almost overnight. We could suddenly find ourselves with a 1 for 1 pfizer swap (and I think that's conservative) if just one data set tilts the scale. Retail's always the last to know.
Causes one to speculate that FDA's threshold for approval is based upon a rather lopsided 1 part Safety/99 parts Efficacy.
and the "abuse of process" that couldn't be more routinely demonstrated when said firms win judgements of $15m and disburse checks to the injured class in the amount of $1.13 How this has escaped racketeering for so long, and how any sane judge can be a party to this, boggles the mind
Post-of-the-day
Anyone who's still holding fast over the last 3+ years likely has the marrow. People keep asking where the floor is on SP, but the question's morphing into "where's the floor on the economy". This "recovery" has been reluctant to build value for an unusually protracted length of time for good reason- never in history has every major nation been more underwater with debt. Bogus metrics (jobs figures etc) gloss over reality. EE's prediction isn't far fetched. I've bet on my ctix play making its first touchdown before the market gets its clock cleaned, or at least being in a position to outpace the carnage.
I said early on there was good reason why he fought so hard for those shares. He (and big red) both think there's a there there
Nothing like a little spirited COMPETITION to stick a pin in those putzes over at DF. Mayo will run circles around 'em!
If Leo could just tie our research to climate change, we'd be rolling in grants..
My confidence vortex asks, any idea as to the location/nationality of this CRO?
Buy order's in. Feels like a good day to stock up.
What inflated sense of entitlement that any lawyer should presume to bring such a shoddy and subjective case to a court.. to use the term "scienter" as many times as they have reminds me of the kid who blurts out "Someone farted" five seconds before the air goes bad. Would it be trite to quote Dick the Butcher?
seems both plaintiff and defendant are plagued with "scrivener's errors". A proofreader rather than a judge would be my remedy. To bring a complaint- an AMENDED complaint ordered due to the deficiency of the original, no less, without so much as a 5th grade review of syntax is insulting to Failla and the court. I'd throw Kim et al outta there so fast their ass would leave their underwear
I get a kick out of the fact that they've made the very centerpiece of their complaint, that Kerala U actually conferred the PhD rather than Harvard, despite his Harvard work.. It's my understanding that this was corrected/clarified many years before the dates appertaining to the class. A class arising from 2009 could conceivably have some measure of standing, but this Johnny-come-lately? Fishing expedition.
Time for tax loss is done & gone, and don't think I didn't seriously consider it. At this point I'm in this for another year. Too many things feel too close to breaking out for me to short this one. Potential for B alone is simply mind-boggling. Sittin tight for data.
My plans to attend fell through as my father-in-law died several days ago. This meeting will surely be attended by some of our most diligent shareholders, and in that I take solace. Best wishes and safe travels to all of you! And for heaven's sake, someone PLEASE pull out a phone and POST SOME PICS of Menon, Ehrlich, et al
Rope a dope anyone? Perhaps someone should create a pseudonym, then proceed to write an elaborate hit piece on Mako replete with embarrassing (stock) photos, (contrived) scandals, and a daisy chain of (quite real)federal crimes, then wait for him to sue us. Hmm.. He/she/they'd either have to emerge from beneath their rock to sue, or let the lie stand (a la S.A. 8/6/15) Were I only rat bastard enough to pull it off
Ha! a "pack" with one blister.. Somehow that cheapens the image. We need the Marketing guys to come up w/ something special for the packaging- I'm thinking a glass ampule with platinum anodes suspending the B pill in nitrogen, surrounded by a protective cage matrix, complete with LCD status readouts. Naturally, it's gotta "hiss" when opened..
# of CTIX Board followers might be understated. I only recently found the "follow" link among Ihub's clutter, but I've been around for years. Good to see you posting again
offensive strategy's in order- maybe time to consult the ol' ball coach
I get the same feeling. Hat's off to Leo for cleverly inserting Ocata into the headline, causing cross-references in news feeds. He's slowly getting PR savvy. FB post re:Mako was a hoot!
The over-the-top effort that went into the Mako piece (and I guarandamntee the author is so multi-layer anonymized no one will ever find him/them), Rosen et al, and the price action that followed smacks of motivated foul play. I get the sense somebody has an serious axe to grind. I also think it's someone who intimately knows the value of Brilacidin. I think there's been an earnest attempt to out-Polyheist our Polyheist. Devaluing SP won't do it due to our insiders percentages, but a BK could knock that ball back into play, a la the original heist. Ok, tin foil hat off, gotta get to my real job where livestock follows an infinitely more definite logic
Dude, this is the FDA we're talking about here.
Its like the DMV, except they wear a different costume.
Lord have mercy! Neither one of our chiefs could return to their house if this went zero bid
Understood, and fair arguments all. Aggravating as these fumbles may be in the short term, and indeed, damaging in aggregate, there is one mitigating factor in my opinion: Leo and company surely now recognize that they are under intense scrutiny from shareholders, competitors and predators alike. When you are acutely aware you're being watched, it would stand to reason that a higher degree of integrity is compulsory. Along this same line of logic, when I wanted safer tires, I switched to Firestones soon after the Ford Explorer debacle. At this moment, I remain highly confident with the diversity of Cellceutix' product line, and the uncommon fact that NONE of our trials have lost a foot in the biotech minefield, execs are NOT selling their shares, and as yet, there is not a hungry hoard of a board wolfing down our cash in half-mil salaries plus milestones and options every quarter, followed by shelf after split. Things COULD be really ugly, were this some other biotech.
Sox, Chris Hackett of terrapinn (director of conference program and speaking opportunities) emailed me yesterday at 1307 that he was unable to reach KM at 1100, and that he made the call to re allocate said time to the remaining presenters. I've received no further information from him.
Ugh Reverse split..Just what I dream of- half my shares with no change in fundamentals. RS wouldn't give us an hours' boost, imo, and would likely be seen as an act of desperation, Nasdaq'd probably remain aloof, then comes shelf- NO thank you. While value builds with milestones only revenue will raise the bid. Immediate revenue. SP will continue on this trajectory until that happens. God only knows when the first substantial catalyst will happen- but I'm banking on sooner rather than later as evidenced by my very disproportionate position here. I appreciate that this roller coaster affects us all differently. Some scream, some want off, and some will hurl. Instinct, however, tells me something good is about to happen.
In my observation, IMMINENT revenue/buyout offer is the only good news that will sustainably lift the SP. All other good news is merely academic
With each fluff piece, I read "Principals have sold no shares" and "No trial has been halted by FDA" (unlike our friends at AD%$ and elsewhere) Fluff = no news, and no news = good news. All information has value- just ask the NSA.
Brilacidin, once all claims are vetted, represents a disruptive technology. As trials reveal more promise, I expect to see a sharp increase in attacks from competitors/special interests with obsolete platforms, which if Cellceutix can defend against, will be followed by a cascade of acquisition offers. (Oh yeah, I keep nearly forgetting we have two other drugs in trials as well)
All in. Not 1 share sold in 3 years. Seen this action time and again (Nasdaq especially)& I'm not shaken. When C-level sells, then my ears perk up. Til then, typical market spasms.
SA has probably been advised that pulling the article would be a de facto admission of guilt/negligence in using due diligence. I think they are in an awkward position, currently relying on your theory of graduated standards existing in "news" publishing
Just received a call from Leo. He was answering a question I'd left earlier this morning re: our transfer agent. He assured me that the company is "going to fight this" regarding the frivolous filings, but that his focus is on our trials and in running the company. Sorry it wasn't a more meaty conversation, as my attention was divided here at work, but our CEO is, as legend has it, unusually accessible to us retails. I have an appreciation for a leadership style that does not run and hide when shareholders come calling. For the record, I am long and still accumulating.